Soleno Therapeutics Stock Performance
| SLNO Stock | USD 46.88 0.89 1.94% |
The entity has a beta of 1.14, which indicates a somewhat significant risk relative to the market. Soleno Therapeutics returns are very sensitive to returns on the market. As the market goes up or down, Soleno Therapeutics is expected to follow. At this point, Soleno Therapeutics has a negative expected return of -0.17%. Please make sure to validate Soleno Therapeutics' total risk alpha, skewness, as well as the relationship between the Skewness and day median price , to decide if Soleno Therapeutics performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Soleno Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of latest weak performance, the Stock's basic indicators remain healthy and the recent disarray on Wall Street may also be a sign of long period gains for the firm investors. ...more
Actual Historical Performance (%)
One Day Return 1.94 | Five Day Return 10.49 | Year To Date Return 2.56 | Ten Year Return (61.18) | All Time Return (83.89) |
Last Split Factor 1:15 | Dividend Date 2017-10-06 | Last Split Date 2022-08-26 |
1 | Soleno Therapeutics Clears Key Benchmark, Hitting 90-Plus RS Rating | 11/25/2024 |
2 | Soleno Therapeutics Announces FDA Extension of Review Period for DCCR Extended-Release Tablets in Prader-Willi Syndrome | 11/26/2024 |
3 | Outperform rating maintained on Soleno Therapeutics stock, regulatory approval outlook strong | 12/02/2024 |
4 | Fmr LLC Boosts Position in Soleno Therapeutics, Inc. - MarketBeat | 12/09/2024 |
5 | Soleno Therapeutics enters into 200M debt financing with Oxford Finance | 12/17/2024 |
6 | Soleno Therapeutics is Now Oversold - Nasdaq | 12/19/2024 |
7 | Prader-Willi Syndrome Treatment Landscape Poised for Transformative Growth by 2034, Reports DelveInsight | 01/02/2025 |
8 | Disposition of 10154 shares by Anish Bhatnagar of Soleno Therapeutics at 46.1764 subject to Rule 16b-3 | 01/03/2025 |
9 | Soleno Therapeutics, Inc. When Will It Breakeven | 01/07/2025 |
10 | Is Soleno Therapeutics the Top Small Cap Stock to Buy with the Highest Upside Potential | 01/13/2025 |
| Begin Period Cash Flow | 14.6 M |
Soleno |
Soleno Therapeutics Relative Risk vs. Return Landscape
If you would invest 5,375 in Soleno Therapeutics on October 21, 2024 and sell it today you would lose (687.00) from holding Soleno Therapeutics or give up 12.78% of portfolio value over 90 days. Soleno Therapeutics is currently does not generate positive expected returns and assumes 3.1454% risk (volatility on return distribution) over the 90 days horizon. In different words, 28% of stocks are less volatile than Soleno, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Soleno Therapeutics Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Soleno Therapeutics' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Soleno Therapeutics, and traders can use it to determine the average amount a Soleno Therapeutics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.055
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | SLNO |
Estimated Market Risk
| 3.15 actual daily | 28 72% of assets are more volatile |
Expected Return
| -0.17 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.05 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Soleno Therapeutics is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Soleno Therapeutics by adding Soleno Therapeutics to a well-diversified portfolio.
Soleno Therapeutics Fundamentals Growth
Soleno Stock prices reflect investors' perceptions of the future prospects and financial health of Soleno Therapeutics, and Soleno Therapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Soleno Stock performance.
| Return On Equity | -0.91 | ||||
| Return On Asset | -0.48 | ||||
| Current Valuation | 1.77 B | ||||
| Shares Outstanding | 43.12 M | ||||
| Price To Earning | (3.71) X | ||||
| Price To Book | 7.64 X | ||||
| EBITDA | (37.03 M) | ||||
| Net Income | (38.99 M) | ||||
| Cash And Equivalents | 24.07 M | ||||
| Cash Per Share | 2.97 X | ||||
| Total Debt | 403 K | ||||
| Debt To Equity | 0.02 % | ||||
| Current Ratio | 3.43 X | ||||
| Book Value Per Share | 6.45 X | ||||
| Cash Flow From Operations | (24.94 M) | ||||
| Earnings Per Share | (2.85) X | ||||
| Market Capitalization | 2.02 B | ||||
| Total Asset | 180.69 M | ||||
| Retained Earnings | (276.41 M) | ||||
| Working Capital | 159.85 M | ||||
About Soleno Therapeutics Performance
By examining Soleno Therapeutics' fundamental ratios, stakeholders can obtain critical insights into Soleno Therapeutics' financial health, operational efficiency, and overall profitability. These insights assist in making well-informed investment and management decisions. For example, a high Return on Assets and Return on Equity would indicate that Soleno Therapeutics is effectively utilizing its assets and equity to generate significant profits, enhancing its appeal to investors. On the other hand, low ROA and ROE values could reveal issues in asset and equity management, highlighting the need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 183.66 | 174.48 | |
| Return On Tangible Assets | (0.20) | (0.21) | |
| Return On Capital Employed | (0.28) | (0.30) | |
| Return On Assets | (0.19) | (0.20) | |
| Return On Equity | (0.28) | (0.30) |
Things to note about Soleno Therapeutics performance evaluation
Checking the ongoing alerts about Soleno Therapeutics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Soleno Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Soleno Therapeutics generated a negative expected return over the last 90 days | |
| Soleno Therapeutics has high historical volatility and very poor performance | |
| Soleno Therapeutics has high likelihood to experience some financial distress in the next 2 years | |
| Net Loss for the year was (38.99 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Soleno Therapeutics currently holds about 24.07 M in cash with (24.94 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.97. | |
| Over 97.0% of the company shares are owned by institutional investors | |
| Latest headline from insidermonkey.com: Is Soleno Therapeutics the Top Small Cap Stock to Buy with the Highest Upside Potential |
- Analyzing Soleno Therapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Soleno Therapeutics' stock is overvalued or undervalued compared to its peers.
- Examining Soleno Therapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Soleno Therapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Soleno Therapeutics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Soleno Therapeutics' stock. These opinions can provide insight into Soleno Therapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Soleno Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. To learn how to invest in Soleno Stock, please use our How to Invest in Soleno Therapeutics guide.You can also try the Portfolio Diagnostics module to use generated alerts and portfolio events aggregator to diagnose current holdings.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Soleno Therapeutics. If investors know Soleno will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Soleno Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Soleno Therapeutics is measured differently than its book value, which is the value of Soleno that is recorded on the company's balance sheet. Investors also form their own opinion of Soleno Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Soleno Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Soleno Therapeutics' market value can be influenced by many factors that don't directly affect Soleno Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Soleno Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Soleno Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Soleno Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.